Faculty Profiles - TAKAHASHI, Yoshiyuki

Papers - TAKAHASHI, Yoshiyuki

Division display 161 - 180 of about 483 ／ All the affair displays >>

Prolonged Hospitalization and Late Gastroenterological Complications in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Nozomu Kawashima, Shinsuke Kataoka, Motoharu Hamada, Eri Nishikawa, Rieko Taniguchi, Atsushi Narita, Hideki Muramatsu, Nobuhiro Nishio, Yoshiyuki Takahashi

PEDIATRIC BLOOD & CANCER Vol. 68 2021.11

がん遺伝子パネル検査でBRAF V600E変異を認めた副腎腫瘍の16歳女性

佐治木大知, 村松秀城, 津村悠介, 前村遼, 今屋雅之, 山森彩子, 若松学, 吉田太郎, 三輪田俊介, 成田幸太郎, 市川大輔, 濱田太立, 谷口理恵子, 鈴木喬悟, 川島希, 西川英里, 成田敦, 西尾信博, 高橋義行, 島田聡子, 榊原綾子, 下山芳江, 岩淵英人

日本小児血液・がん学会雑誌 Vol. 58 ( 3 ) page： 325 - 326 2021.11

Hematopoietic stem cell transplantation for infants with high-risk KMT2A gene-rearranged acute lymphoblastic leukemia. International journal Open Access

Takayuki Takachi, Tomoyuki Watanabe, Takako Miyamura, Akiko Moriya Saito, Takao Deguchi, Toshinori Hori, Tomomi Yamada, Shigeru Ohmori, Masami Haba, Yuki Aoki, Sae Ishimaru, Shinya Sasaki, Junjiro Ohshima, Akihiro Iguchi, Yoshiyuki Takahashi, Nobuyuki Hyakuna, Atsushi Manabe, Keizo Horibe, Eiichi Ishii, Katsuyoshi Koh, Daisuke Tomizawa

Blood advances Vol. 5 ( 19 ) page： 3891 - 3899 2021.10

Language：English Publishing type：Research paper (scientific journal)

The role of allogeneic hematopoietic stem cell transplantation (HSCT) for infants with acute lymphoblastic leukemia (ALL) and KMT2A gene rearrangement (KMT2A-r) is controversial in terms of both its efficacy and potential for acute and late toxicities. In Japanese Pediatric Leukemia/Lymphoma Study Group trial MLL-10, by introducing intensive chemotherapy, indication of HSCT was restricted to patients with high-risk (HR) features only (KMT2A-r and either age <180 days or presence of central nervous system leukemia). Of the 56 HR patients, 49 achieved complete remission. Forty-three patients received HSCT in first remission including 38 patients receiving protocol-specified HSCT with conditioning consisting of individualized targeted doses of busulfan, etoposide, and cyclophosphamide. Three-year event-free survival (EFS) of 56.8% (95% confidence interval [CI], 42.4% to 68.8%) and overall survival of 80.2% (95% CI, 67.1% to 88.5%) were accomplished. Univariable analysis showed that Interfant-HR criteria and flow cytometric minimal residual disease (MRD; ≥0.01%), both at the end of induction and at the end of consolidation (EOC), were significantly associated with poorer EFS. In the multivariable analysis, positive MRD at EOC was solely associated with poor EFS (P < .001). Rapid pretransplant MRD clearance and tailored HSCT strategy in the MLL-10 trial resulted in a favorable outcome for infants with HR KMT2A-r ALL. However, considering the high rate of potentially life-threatening toxicities and the risk of late effects, its indication should be further restricted or even eliminated in the future by introducing more effective therapeutic modalities with minimal toxicities. This trial was registered at the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) as #UMIN000004801.

DOI： 10.1182/bloodadvances.2020004157

Open Access

Web of Science

PubMed

Single-Arm Non-Blinded Multicenter Clinical Trial on T-Cell-Replete Haploidentical Stem Cell Transplantation Using Low-Dose Antithymocyte Globulin for Relapsed and Refractory Pediatric Acute Leukemia.

Kada A, Kikuta A, Saito AM, Kato K, Iguchi A, Yabe H, Ishida H, Hyakuna N, Takahashi Y, Nagasawa M, Hashii Y, Umeda K, Matsumoto K, Fujisaki H, Yano M, Nakazawa Y, Sano H

The Kurume medical journal Vol. 66 ( 3 ) page： 161 - 168 2021.10

Clinical Images: Extensive multiple organ involvement in VEXAS syndrome Open Access

Takahashi, N; Takeichi, T; Nishida, T; Sato, J; Takahashi, Y; Yamamura, M; Ogi, T; Akiyama, M

ARTHRITIS & RHEUMATOLOGY Vol. 73 ( 10 ) page： 1896 - 1897 2021.10

Acquisition of a rare NUP98-BPTF fusion gene associated with recurrence of acute myeloid leukemia. International journal

Koji Kawaguchi, Shohei Azumi, Yosuke Itakura, Takayuki Takachi, Taemi Ogura, Yasuo Horikoshi, Kyogo Suzuki, Hideki Muramatsu, Asahito Hama, Yoshiyuki Takahashi, Kenichiro Watanabe

Pediatric blood & cancer Vol. 68 ( 10 ) page： e29201 2021.10

腹水ドレナージとデフィブロタイドが奏功した急性リンパ性白血病に対する骨髄移植後Veno-Occlusive Disease(Successful Therapy with Ascites Drainage and Defibrotide for Veno-Occlusive Disease Developed After Bone marrow Transplantation in Acute Lymphoblastic Leukemia)

Maemura Ryo, Narita Atsushi, Kataoka Shinsuke, Taniguchi Rieko, Hamada Motoharu, Nishikawa Eri, Kawashima Nozomu, Nishio Nobuhiro, Muramatsu Hideki, Takahashi Yoshiyuki

日本小児血液・がん学会雑誌 Vol. 58 ( 4 ) page： 246 - 246 2021.10

神経芽腫における尿中バイオマーカー(Urinary biomarkers predicting treatment outcomes in neuroblastoma)

Narita Atsushi, Hinoki Akinari, Yokota Kazuki, Hamada Motoharu, Kataoka Shinsuke, Kawashima Nozomu, Muramatsu Hideki, Nishio Nobuhiro, Uchida Hiroo, Takahashi Yoshiyuki

日本小児血液・がん学会雑誌 Vol. 58 ( 4 ) page： 225 - 225 2021.10

小児骨髄不全症候群コホート中のFPD-MMが疑われたRUNX1変異10症例のまとめ(Ten patients with RUNX1 mutation who were suspected with FPD-MM in a pediatric cohort of inherited bone marrow failure syndrome)

Yamamori Ayako, Hamada Motoharu, Muramatsu Hideki, Taniguchi Rieko, Kataoka Shinsuke, Kawashima Nozomu, Narita Atsushi, Nishio Nobuhiro, Okuno Yusuke, Takahashi Yoshiyuki

日本小児血液・がん学会雑誌 Vol. 58 ( 4 ) page： 214 - 214 2021.10

小児における未分化白血病の臨床的特徴(Clinical features of immature leukemias in children)

Sajiki Daichi, Yoshida Nao, Muramatsu Hideki, Sakaguchi Kimiyoshi, Maeda Naoko, Yokoyama Norifumi, Miyajima Yuji, Tanaka Makito, Takahashi Yoshiyuki, Hama Asahito

日本小児血液・がん学会雑誌 Vol. 58 ( 4 ) page： 185 - 185 2021.10

小児同種移植後に長期入院を要する原因と移植後晩期にみられる消化管合併症(Prolonged Hospitalization and Late Gastroenterological Complications in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation)

Kawashima Nozomu, Kataoka Shinsuke, Hamada Motoharu, Nishikawa Eri, Taniguchi Rieko, Narita Atsushi, Muramatsu Hideki, Nishio Nobuhiro, Takahashi Yoshiyuki

日本小児血液・がん学会雑誌 Vol. 58 ( 4 ) page： 242 - 242 2021.10

単一施設における再発4期神経芽腫に対するKIRリガンド不一致同種臍帯血移植による治療成績(Outcomes of KIR-ligand incompatible allogeneic cord blood transplantation for relapsed stage 4 neuroblastoma: a single institutional study)

Kataoka Shinsuke, Nishio Nobuhiro, Wakamatsu Manabu, Taniguchi Rieko, Nishikawa Eri, Hamada Motoharu, Kawashima Nozomu, Narita Atsushi, Muramatsu Hideki, Takahashi Yoshiyuki

日本小児血液・がん学会雑誌 Vol. 58 ( 4 ) page： 226 - 226 2021.10

化学療法による治療介入を行った生後2ヵ月未満発症の神経芽腫4S(Using chemotherapy to treat neuroblastoma stage 4S with hepatomegaly in a patient younger than 2 months old)

Imaya Masayuki, Nishio Nobuhiro, Taniguchi Rieko, Kataoka Shinsuke, Hamada Motoharu, Nishikawa Eri, Kawashima Nozomu, Narita Atsushi, Muramatsu Hideki, Takahashi Yoshiyuki

日本小児血液・がん学会雑誌 Vol. 58 ( 4 ) page： 225 - 225 2021.10

NGS-MRDに基づくリスク層別化による高リスクALLに対する治療強化(Strategy of intensified therapy for high risk pediatric acute lymphoblastic leukemia based on NGS-MRD-based risk stratification)

Hamada Motoharu, Imaya Masayuki, Okuno Yusuke, Kawashima Nozomu, Taniguchi Rieko, Narita Atsushi, Muramatsu Hideki, Nishio Nobuhiro, Hasegawa Shinji, Takahashi Yoshiyuki

日本小児血液・がん学会雑誌 Vol. 58 ( 4 ) page： 191 - 191 2021.10

CD19-CAR-T細胞療法後に再発したB-ALLに対するCD19-CAR-T細胞の再投与(Re-treatment with CD19-targeted CAR-T cells for relapse after CD19-CAR-T cell therapy)

Nishio Nobuhiro, Hamada Motoharu, Nishikawa Eri, Kawashima Nozomu, Narita Atsushi, Muramatsu Hideki, Wang Kai, Zheng Huyong, Chang Jung-Li, Takahashi Yoshiyuki

日本小児血液・がん学会雑誌 Vol. 58 ( 4 ) page： 191 - 191 2021.10

Usefulness of functional splicing analysis to confirm precise disease pathogenesis in Diamond-Blackfan anemia caused by intronic variants in <i>RPS19</i> Open Access

Takafuji, S; Mori, T; Nishimura, N; Yamamoto, N; Uemura, S; Nozu, K; Terui, K; Toki, T; Ito, E; Muramatsu, H; Takahashi, Y; Matsuo, M; Yamamura, T; Iijima, K

PEDIATRIC HEMATOLOGY AND ONCOLOGY Vol. 38 ( 6 ) page： 515 - 527 2021.9

Clinical diagnostic value of telomere length measurement in inherited bone marrow failure syndromes. International journal Open Access

Shunsuke Miwata, Atsushi Narita, Yusuke Okuno, Kyogo Suzuki, Motoharu Hamada, Taro Yoshida, Masayuki Imaya, Ayako Yamamori, Manabu Wakamatsu, Kotaro Narita, Hironobu Kitazawa, Daisuke Ichikawa, Rieko Taniguchi, Nozomu Kawashima, Eri Nishikawa, Nobuhiro Nishio, Seiji Kojima, Hideki Muramatsu, Yoshiyuki Takahashi

Haematologica Vol. 106 ( 9 ) page： 2511 - 2515 2021.9

Autoantibodies against the plakin family proteins as a novel marker for chronic graft-versus-host disease of the lung. International journal Open Access

Nozomu Kawashima, Eri Nishikawa, Atsunari Tsuchisaka, Takashi Hashimoto, Yusuke Okuno, Motoharu Hamada, Daisuke Ichikawa, Atsushi Narita, Hideki Muramatsu, Nobuhiro Nishio, Seiji Kojima, Yoshinao Muro, Yoshiyuki Takahashi

Bone marrow transplantation Vol. 56 ( 9 ) page： 2291 - 2294 2021.9

Echocardiography Monitoring of Pulmonary Hypertension after Pediatric Hematopoietic Stem Cell Transplantation: Pediatric Pulmonary Arterial Hypertension and Pulmonary Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation. International journal Open Access

Nozomu Kawashima, Yoshie Fukasawa, Eri Nishikawa, Keiko Ohta-Ogo, Hatsue Ishibashi-Ueda, Motoharu Hamada, Daisuke Ichikawa, Atsushi Narita, Yusuke Okuno, Hideki Muramatsu, Nobuhiro Nishio, Seiji Kojima, Taichi Kato, Yoshiyuki Takahashi

Transplantation and cellular therapy Vol. 27 ( 9 ) page： 786.e1 - 786.e8 2021.9

Language：English Publishing type：Research paper (scientific journal)

Pulmonary hypertension (PH) is associated with high morbidity in children undergoing hematopoietic stem cell transplantation (HSCT). However, owing to the lack of sequential echocardiography, the nature of the condition is not fully understood. This study was conducted to investigate whether routine echocardiography performed after HSCT could detect patients with PH at an earlier stage and elucidate the role of intervention using tadalafil. The study population comprised 93 consecutive children age <18 years who underwent a total of 109 HSCTs. All patients underwent routine transthoracic echocardiography during HSCT. Four children (4%) with a median age of 4 years (range, 0.7 to 6 years) were found to have PH, and their median tricuspid regurgitation peak velocity (TRV) was 4.1 m/s (range, 3.5 to 4.2 m/s). PH was diagnosed at a median of 52 days (range, 21 to 118 days) after HSCT. Three of them were diagnosed with neuroblastoma, and 1 was diagnosed with infantile leukemia. One patient developed PH after autologous HSCT, and 3 received killer immunoglobulin-like receptor ligand-mismatched cord blood. Busulfan was used for conditioning in all patients, and the proportion of patients receiving this medication was significantly higher in the PH group compared with the non-PH group (100% versus 30%; P = .011). Three of the 4 patients had a durable response (TRV ≤2.8 m/s) at a median of 46 days (range, 14 to 79 days) after starting treatment with tadalafil. No patient experienced exacerbation of PH, and treatment was completed at median of 96 days (range, 46 to 212 days). Our data suggest that routine echocardiography monitoring after HSCT should be considered in children receiving busulfan, although the precise follow-up timing needs further study. In addition, safe and effective administration of tadalafil must be ensured by close monitoring.

DOI： 10.1016/j.jtct.2021.05.017

Open Access

Web of Science

PubMed

Effect of high-dose chemotherapy plus stem cell rescue on the survival of patients with neuroblastoma modified by MYCN gene gain/amplification and remission status: a nationwide registration study in Japan. International journal

Yuya Saito, Mitsuyoshi Urashima, Yoshiyuki Takahashi, Atsushi Ogawa, Chikako Kiyotani, Yuki Yuza, Katsuyoshi Koh, Kenichiro Watanabe, Yoshiyuki Kosaka, Hiroaki Goto, Atsushi Kikuta, Keiko Okada, Yuhki Koga, Junya Fujimura, Masami Inoue, Atsushi Sato, Yoshiko Atsuta, Kimikazu Matsumoto

Bone marrow transplantation Vol. 56 ( 9 ) page： 2173 - 2182 2021.9

Language：English Publishing type：Research paper (scientific journal)

In high-risk neuroblastoma, the presence of an MYCN gain/amplification (MYCN-GA) is not always a risk factor of cancer-specific death. We herein examined the effect modification of high-dose chemotherapy with autologous hematopoietic stem cell rescue (HDC-autoSCR) in terms of the interaction between MYCN status and remission status (complete remission or very good partial remission [CR/VGPR] vs. partial remission or less [≤PR]). The present study recruited patient data from 1992 to 2017 in the Japan Society of Hematopoietic Cell Transplantation's national registry. The MYCN status was known in 586 of 950 patients with a single course of HDC-autoSCR. Cumulative hazard curves for neuroblastoma-specific death showed that a subgroup with MYCN-GA and ≤PR had a significantly poorer prognosis than three other subgroups, namely, the MYCN-NGA/ ≤ PR, MYCN-NGA/CR/VGPR, and MYCN-GA/CR/VGPR subgroups even after adjusting for non-infants and stage IV disease (hazard ratio: 2.79; 95% confidence interval: 1.91-4.09; P < 0.001). The interaction between MYCN-GA and ≤PR was significant (pinteraction = 0.006). Hence, the patients with MYCN-GA with non-remission status at HDC-autoSCR had a significantly poorer prognosis than the other subgroups, suggesting that HDC-autoSCR may be effective in patients with CR/VGPR regardless of MYCN gene status and in patients with MYCN-NGA regardless of remission status.

DOI： 10.1038/s41409-021-01303-z

Web of Science

PubMed

　 PREV - NEXT 　

<TAKAHASHI, Yoshiyuki>

Papers - TAKAHASHI, Yoshiyuki